 Rohit Katial
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 59 | 2025 | 1920 | 6.600 |
Why?
| | Anti-Asthmatic Agents | 26 | 2025 | 273 | 5.150 |
Why?
| | Biological Products | 13 | 2025 | 239 | 2.810 |
Why?
| | Hypersensitivity | 9 | 2024 | 260 | 2.770 |
Why?
| | Aspirin | 11 | 2018 | 385 | 2.580 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 181 | 2.160 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 22 | 2.120 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 27 | 2.100 |
Why?
| | Sinusitis | 11 | 2024 | 239 | 2.030 |
Why?
| | Adrenal Cortex Hormones | 16 | 2025 | 501 | 1.690 |
Why?
| | Rhinitis | 7 | 2024 | 173 | 1.530 |
Why?
| | Eosinophils | 17 | 2025 | 326 | 1.460 |
Why?
| | Nitric Oxide | 8 | 2024 | 900 | 1.360 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 348 | 1.350 |
Why?
| | Nasal Polyps | 7 | 2024 | 61 | 1.290 |
Why?
| | Antibodies, Monoclonal, Humanized | 16 | 2024 | 913 | 1.270 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 329 | 1.250 |
Why?
| | Rhinitis, Allergic | 4 | 2024 | 42 | 1.230 |
Why?
| | Allergens | 7 | 2024 | 401 | 1.160 |
Why?
| | Immunoglobulin E | 7 | 2025 | 331 | 1.150 |
Why?
| | Eosinophilia | 7 | 2024 | 226 | 1.140 |
Why?
| | Skin Tests | 3 | 2024 | 97 | 1.110 |
Why?
| | Histamine Antagonists | 4 | 2011 | 20 | 1.090 |
Why?
| | Mast Cells | 3 | 2023 | 153 | 1.030 |
Why?
| | Cost of Illness | 3 | 2024 | 313 | 0.990 |
Why?
| | Exhalation | 2 | 2018 | 29 | 0.960 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 42 | 0.950 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 95 | 0.950 |
Why?
| | Humans | 116 | 2025 | 141754 | 0.860 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 72 | 0.860 |
Why?
| | Angioedema | 1 | 2024 | 16 | 0.850 |
Why?
| | Immunotherapy | 5 | 2017 | 646 | 0.840 |
Why?
| | Severity of Illness Index | 14 | 2025 | 2903 | 0.830 |
Why?
| | Mastocytosis | 1 | 2023 | 12 | 0.820 |
Why?
| | Urticaria | 1 | 2024 | 39 | 0.820 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 109 | 0.810 |
Why?
| | Remission Induction | 6 | 2025 | 309 | 0.800 |
Why?
| | Gastritis | 1 | 2024 | 118 | 0.770 |
Why?
| | Enteritis | 1 | 2024 | 107 | 0.770 |
Why?
| | Deglutition Disorders | 1 | 2024 | 151 | 0.760 |
Why?
| | Biomarkers | 10 | 2025 | 4190 | 0.750 |
Why?
| | Allergy and Immunology | 2 | 2024 | 41 | 0.690 |
Why?
| | Pancreatitis | 2 | 2012 | 136 | 0.690 |
Why?
| | Albuterol | 3 | 2010 | 75 | 0.690 |
Why?
| | Breath Tests | 4 | 2007 | 77 | 0.650 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 437 | 0.650 |
Why?
| | Androstadienes | 2 | 2010 | 78 | 0.650 |
Why?
| | Sputum | 4 | 2024 | 313 | 0.620 |
Why?
| | Drug Hypersensitivity | 4 | 2016 | 95 | 0.590 |
Why?
| | Antibodies, Monoclonal | 4 | 2025 | 1474 | 0.580 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 50 | 0.560 |
Why?
| | Biological Therapy | 1 | 2017 | 27 | 0.510 |
Why?
| | Adult | 46 | 2025 | 39391 | 0.510 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 27 | 0.490 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 13 | 0.480 |
Why?
| | Middle Aged | 36 | 2025 | 34647 | 0.460 |
Why?
| | Administration, Intranasal | 6 | 2011 | 92 | 0.450 |
Why?
| | Practice Guidelines as Topic | 7 | 2024 | 1570 | 0.440 |
Why?
| | Anaphylaxis | 1 | 2016 | 107 | 0.430 |
Why?
| | Vaccination | 3 | 2012 | 1472 | 0.430 |
Why?
| | Double-Blind Method | 10 | 2025 | 1989 | 0.420 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 484 | 0.400 |
Why?
| | Male | 44 | 2025 | 70179 | 0.390 |
Why?
| | Treatment Outcome | 20 | 2025 | 11181 | 0.390 |
Why?
| | Female | 46 | 2025 | 75943 | 0.380 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 104 | 0.360 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 415 | 0.360 |
Why?
| | Chronic Disease | 9 | 2024 | 1820 | 0.350 |
Why?
| | Young Adult | 14 | 2025 | 13749 | 0.340 |
Why?
| | Disease Progression | 5 | 2023 | 2800 | 0.340 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 27 | 0.330 |
Why?
| | Aged | 15 | 2025 | 24746 | 0.320 |
Why?
| | Dermatitis, Atopic | 2 | 2024 | 331 | 0.320 |
Why?
| | Acetates | 1 | 2010 | 82 | 0.310 |
Why?
| | Vaccines | 2 | 2004 | 406 | 0.300 |
Why?
| | Nose | 1 | 2009 | 65 | 0.290 |
Why?
| | Adolescent | 15 | 2025 | 22130 | 0.290 |
Why?
| | Quinolines | 1 | 2010 | 172 | 0.290 |
Why?
| | Laryngismus | 1 | 2008 | 11 | 0.280 |
Why?
| | Leukotriene E4 | 1 | 2008 | 24 | 0.280 |
Why?
| | United States | 7 | 2024 | 15310 | 0.280 |
Why?
| | Vocal Cords | 1 | 2008 | 32 | 0.280 |
Why?
| | Immunity, Cellular | 2 | 2007 | 269 | 0.280 |
Why?
| | Diagnosis, Differential | 5 | 2017 | 1502 | 0.260 |
Why?
| | Quality of Life | 6 | 2025 | 3014 | 0.250 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 207 | 0.250 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 84 | 0.250 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 182 | 0.250 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 394 | 0.240 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.240 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 133 | 0.240 |
Why?
| | Respiratory Tract Infections | 2 | 2004 | 385 | 0.240 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 8 | 0.230 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2025 | 27 | 0.230 |
Why?
| | Nebulizers and Vaporizers | 3 | 2015 | 68 | 0.230 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 5 | 0.230 |
Why?
| | Alternaria | 2 | 2002 | 11 | 0.230 |
Why?
| | Immunoglobulin G | 2 | 2025 | 900 | 0.220 |
Why?
| | Heartburn | 1 | 2024 | 12 | 0.220 |
Why?
| | Anesthetics, Local | 1 | 2005 | 101 | 0.220 |
Why?
| | Cytokines | 3 | 2016 | 2100 | 0.220 |
Why?
| | Analgesia | 1 | 2005 | 102 | 0.220 |
Why?
| | Gastroesophageal Reflux | 2 | 2024 | 244 | 0.220 |
Why?
| | Serum Sickness | 1 | 2004 | 6 | 0.220 |
Why?
| | Syphilis | 1 | 2004 | 35 | 0.220 |
Why?
| | Antigens, Bacterial | 2 | 2002 | 125 | 0.210 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 82 | 0.210 |
Why?
| | Exanthema | 1 | 2004 | 81 | 0.210 |
Why?
| | Bioterrorism | 1 | 2004 | 31 | 0.210 |
Why?
| | Registries | 7 | 2025 | 2144 | 0.210 |
Why?
| | Bupropion | 1 | 2004 | 46 | 0.210 |
Why?
| | Administration, Inhalation | 3 | 2016 | 594 | 0.210 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 60 | 0.210 |
Why?
| | Child | 10 | 2025 | 22414 | 0.210 |
Why?
| | Cockroaches | 1 | 2003 | 22 | 0.210 |
Why?
| | Geography | 1 | 2024 | 201 | 0.200 |
Why?
| | Signal Transduction | 2 | 2016 | 5169 | 0.200 |
Why?
| | Research Design | 1 | 2009 | 1146 | 0.200 |
Why?
| | Glycoproteins | 2 | 2002 | 358 | 0.200 |
Why?
| | Recurrence | 2 | 2017 | 1111 | 0.190 |
Why?
| | Consensus | 1 | 2025 | 547 | 0.190 |
Why?
| | Lolium | 1 | 2002 | 2 | 0.190 |
Why?
| | Age of Onset | 1 | 2024 | 534 | 0.190 |
Why?
| | Poaceae | 1 | 2002 | 60 | 0.180 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 16 | 0.180 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 25 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2016 | 792 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 111 | 0.180 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 70 | 0.180 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 1057 | 0.180 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 139 | 0.180 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 64 | 0.180 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 62 | 0.180 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 29 | 0.180 |
Why?
| | Tuberculin | 1 | 2001 | 8 | 0.170 |
Why?
| | Hypersensitivity, Delayed | 1 | 2001 | 30 | 0.170 |
Why?
| | Tuberculin Test | 1 | 2001 | 36 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 196 | 0.170 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2025 | 360 | 0.170 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 8 | 0.170 |
Why?
| | Reference Values | 4 | 2007 | 807 | 0.160 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2001 | 130 | 0.160 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 14 | 0.150 |
Why?
| | Algorithms | 4 | 2020 | 1768 | 0.150 |
Why?
| | Lung | 2 | 2007 | 4137 | 0.150 |
Why?
| | Drug Combinations | 2 | 2010 | 368 | 0.150 |
Why?
| | Chickenpox Vaccine | 1 | 1999 | 74 | 0.150 |
Why?
| | Histamine | 2 | 2011 | 59 | 0.150 |
Why?
| | Tosyl Compounds | 1 | 1998 | 16 | 0.150 |
Why?
| | Theophylline | 1 | 1998 | 43 | 0.140 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 71 | 0.140 |
Why?
| | Bacterial Capsules | 2 | 2012 | 31 | 0.140 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 27 | 0.140 |
Why?
| | Lamiaceae | 1 | 1997 | 2 | 0.140 |
Why?
| | Artemisia | 1 | 1997 | 7 | 0.140 |
Why?
| | Plants, Medicinal | 1 | 1997 | 25 | 0.140 |
Why?
| | Meteorological Concepts | 1 | 1997 | 6 | 0.140 |
Why?
| | Mycobacterium tuberculosis | 1 | 2001 | 320 | 0.130 |
Why?
| | Drug Therapy, Combination | 3 | 2023 | 1041 | 0.130 |
Why?
| | Spores, Fungal | 1 | 1997 | 21 | 0.130 |
Why?
| | Lymphocytosis | 1 | 1997 | 11 | 0.130 |
Why?
| | Benzamides | 1 | 2018 | 221 | 0.130 |
Why?
| | Leukocyte Count | 3 | 2025 | 328 | 0.130 |
Why?
| | Air Microbiology | 1 | 1997 | 48 | 0.130 |
Why?
| | Cohort Studies | 5 | 2025 | 5815 | 0.130 |
Why?
| | Pyrroles | 1 | 2018 | 210 | 0.130 |
Why?
| | Primary Health Care | 1 | 2008 | 1809 | 0.130 |
Why?
| | Aging | 1 | 2007 | 1924 | 0.130 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 30 | 0.130 |
Why?
| | Leukotrienes | 1 | 2016 | 36 | 0.130 |
Why?
| | Allergists | 1 | 2016 | 11 | 0.130 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 420 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 101 | 0.130 |
Why?
| | Interleukin-4 | 3 | 2013 | 215 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1178 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 1997 | 105 | 0.120 |
Why?
| | Administration, Oral | 2 | 2025 | 803 | 0.120 |
Why?
| | Comorbidity | 4 | 2024 | 1664 | 0.120 |
Why?
| | Venoms | 1 | 2016 | 28 | 0.120 |
Why?
| | Interleukins | 2 | 2013 | 251 | 0.120 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 38 | 0.120 |
Why?
| | Herpesvirus 3, Human | 1 | 1999 | 336 | 0.120 |
Why?
| | Insecta | 1 | 2016 | 72 | 0.120 |
Why?
| | Canada | 1 | 2017 | 429 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 482 | 0.110 |
Why?
| | Epinephrine | 1 | 2016 | 148 | 0.110 |
Why?
| | Drugs, Generic | 1 | 2015 | 25 | 0.110 |
Why?
| | Cardiac Tamponade | 1 | 1994 | 14 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 1998 | 574 | 0.110 |
Why?
| | Bronchial Diseases | 1 | 1994 | 37 | 0.110 |
Why?
| | Papilloma | 1 | 1994 | 52 | 0.110 |
Why?
| | Tumor Virus Infections | 1 | 1994 | 50 | 0.110 |
Why?
| | Pentamidine | 1 | 1994 | 3 | 0.110 |
Why?
| | Gallium Radioisotopes | 1 | 1994 | 14 | 0.110 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 35 | 0.110 |
Why?
| | Phosphorylation | 2 | 2016 | 1774 | 0.110 |
Why?
| | Papillomaviridae | 1 | 1994 | 133 | 0.100 |
Why?
| | Basophils | 2 | 2013 | 72 | 0.100 |
Why?
| | Animals | 7 | 2017 | 37749 | 0.100 |
Why?
| | Aerosols | 3 | 2001 | 181 | 0.100 |
Why?
| | Bronchiectasis | 1 | 1994 | 113 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2002 | 855 | 0.100 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1994 | 128 | 0.100 |
Why?
| | Cluster Analysis | 2 | 2025 | 521 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2096 | 0.100 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 178 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 275 | 0.100 |
Why?
| | Drug Resistance | 1 | 2013 | 150 | 0.100 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 2 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2938 | 0.100 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 5 | 0.100 |
Why?
| | Rabies Vaccines | 1 | 2012 | 3 | 0.100 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.100 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 30 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 750 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2016 | 2007 | 0.090 |
Why?
| | Receptors, Histamine | 1 | 2011 | 2 | 0.090 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 28 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2012 | 117 | 0.090 |
Why?
| | Therapeutic Equivalency | 2 | 2025 | 32 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 61 | 0.090 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 139 | 0.090 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 22 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2024 | 16374 | 0.090 |
Why?
| | Fluticasone | 1 | 2010 | 56 | 0.080 |
Why?
| | Health Surveys | 2 | 2012 | 513 | 0.080 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 331 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 330 | 0.080 |
Why?
| | Phenotype | 2 | 2017 | 3177 | 0.080 |
Why?
| | Medication Adherence | 1 | 2014 | 513 | 0.080 |
Why?
| | Cyclopropanes | 1 | 2010 | 78 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 1994 | 382 | 0.080 |
Why?
| | Receptors, IgG | 1 | 2009 | 77 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 166 | 0.080 |
Why?
| | Congresses as Topic | 1 | 2011 | 230 | 0.080 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 10 | 0.080 |
Why?
| | Chemokines, CC | 1 | 2009 | 34 | 0.070 |
Why?
| | Sulfides | 1 | 2010 | 86 | 0.070 |
Why?
| | Bone Marrow | 2 | 2013 | 302 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 80 | 0.070 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 212 | 0.070 |
Why?
| | Clinical Competence | 1 | 2016 | 1205 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2016 | 3597 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2025 | 656 | 0.070 |
Why?
| | Interleukin-13 | 1 | 2009 | 149 | 0.070 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 30 | 0.070 |
Why?
| | Adenosine | 1 | 2009 | 253 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2009 | 330 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 65 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 674 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1115 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2018 | 6289 | 0.060 |
Why?
| | Health Status | 1 | 2012 | 824 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 554 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 498 | 0.060 |
Why?
| | Flushing | 1 | 2005 | 2 | 0.060 |
Why?
| | Administration, Topical | 1 | 2005 | 150 | 0.060 |
Why?
| | Penicillin G | 1 | 2004 | 7 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 28 | 0.060 |
Why?
| | New Zealand | 1 | 2025 | 55 | 0.060 |
Why?
| | Area Under Curve | 1 | 2025 | 324 | 0.060 |
Why?
| | Healthy Volunteers | 1 | 2025 | 215 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1010 | 0.060 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 1 | 0.050 |
Why?
| | Mutation | 1 | 2016 | 4015 | 0.050 |
Why?
| | Dependovirus | 1 | 2025 | 77 | 0.050 |
Why?
| | Clostridium botulinum | 1 | 2004 | 4 | 0.050 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 7 | 0.050 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 9 | 0.050 |
Why?
| | Infant | 1 | 2018 | 9843 | 0.050 |
Why?
| | China | 1 | 2025 | 220 | 0.050 |
Why?
| | Biomedical Research | 1 | 2011 | 708 | 0.050 |
Why?
| | Diarrhea | 1 | 2005 | 184 | 0.050 |
Why?
| | Placebos | 2 | 2018 | 198 | 0.050 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 24 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1158 | 0.050 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 63 | 0.050 |
Why?
| | Yersinia pestis | 1 | 2004 | 45 | 0.050 |
Why?
| | Francisella tularensis | 1 | 2004 | 33 | 0.050 |
Why?
| | Headache | 1 | 2004 | 153 | 0.050 |
Why?
| | Insect Control | 1 | 2003 | 18 | 0.050 |
Why?
| | Food Contamination | 1 | 2003 | 55 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2025 | 336 | 0.050 |
Why?
| | Child, Preschool | 1 | 2018 | 11512 | 0.050 |
Why?
| | Classification | 1 | 2003 | 43 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 240 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 54 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 69 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 554 | 0.050 |
Why?
| | Viral Vaccines | 1 | 2004 | 107 | 0.050 |
Why?
| | Disaster Planning | 1 | 2004 | 97 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 10 | 0.050 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2023 | 97 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2025 | 315 | 0.050 |
Why?
| | Insurance Claim Review | 1 | 2022 | 85 | 0.050 |
Why?
| | Consumer Product Safety | 1 | 2002 | 33 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2008 | 799 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 36 | 0.050 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 11 | 0.050 |
Why?
| | Menstruation | 1 | 2002 | 42 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1268 | 0.050 |
Why?
| | Drug Tolerance | 1 | 2002 | 105 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 6966 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1363 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 1994 | 2567 | 0.040 |
Why?
| | Mycobacterium avium | 1 | 2001 | 21 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 146 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7923 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1498 | 0.040 |
Why?
| | Plant Extracts | 1 | 2002 | 212 | 0.040 |
Why?
| | Ultrasonic Therapy | 1 | 2000 | 15 | 0.040 |
Why?
| | Health Care Costs | 1 | 2023 | 427 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 72 | 0.040 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 435 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 1048 | 0.040 |
Why?
| | Neutrophils | 2 | 2017 | 1282 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1448 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1094 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2902 | 0.040 |
Why?
| | Phenylcarbamates | 1 | 1998 | 4 | 0.040 |
Why?
| | Leukotriene Antagonists | 1 | 1998 | 24 | 0.040 |
Why?
| | Uricosuric Agents | 1 | 1998 | 2 | 0.040 |
Why?
| | Probenecid | 1 | 1998 | 8 | 0.040 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 14 | 0.040 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 8 | 0.040 |
Why?
| | Methacholine Chloride | 1 | 2018 | 50 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 386 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 7092 | 0.040 |
Why?
| | Pokeweed Mitogens | 1 | 1998 | 7 | 0.040 |
Why?
| | Phytohemagglutinins | 1 | 1998 | 29 | 0.040 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 10 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 587 | 0.040 |
Why?
| | Concanavalin A | 1 | 1998 | 75 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2013 | 4212 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2018 | 85 | 0.030 |
Why?
| | Immunocompetence | 1 | 1998 | 44 | 0.030 |
Why?
| | Mitogens | 1 | 1998 | 59 | 0.030 |
Why?
| | Equipment Design | 2 | 2015 | 525 | 0.030 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1997 | 26 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 560 | 0.030 |
Why?
| | Pollen | 1 | 1997 | 22 | 0.030 |
Why?
| | Cladosporium | 1 | 1997 | 1 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2765 | 0.030 |
Why?
| | Mitosporic Fungi | 1 | 1997 | 7 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2010 | 5212 | 0.030 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1997 | 52 | 0.030 |
Why?
| | Organophosphonates | 1 | 1998 | 99 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 1130 | 0.030 |
Why?
| | Cross Reactions | 1 | 1997 | 133 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 175 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 161 | 0.030 |
Why?
| | Herpes Simplex | 1 | 1998 | 95 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 1997 | 123 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 336 | 0.030 |
Why?
| | Immunoblotting | 1 | 1997 | 310 | 0.030 |
Why?
| | Drug Interactions | 1 | 1998 | 406 | 0.030 |
Why?
| | Superantigens | 1 | 1997 | 70 | 0.030 |
Why?
| | Enterotoxins | 1 | 1997 | 88 | 0.030 |
Why?
| | Immunization | 1 | 1999 | 406 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 235 | 0.030 |
Why?
| | Prognosis | 1 | 2005 | 4080 | 0.030 |
Why?
| | JC Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5974 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 582 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 175 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5697 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 881 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2015 | 31 | 0.030 |
Why?
| | Biopsy | 2 | 2011 | 1083 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2608 | 0.030 |
Why?
| | IgA Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Pericarditis | 1 | 1994 | 11 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1999 | 1150 | 0.030 |
Why?
| | Seasons | 1 | 1997 | 546 | 0.030 |
Why?
| | Indoles | 1 | 1998 | 478 | 0.030 |
Why?
| | Sulfonamides | 1 | 1998 | 567 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 1994 | 120 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 158 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1866 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 241 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 861 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 378 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 6 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 21 | 0.030 |
Why?
| | Risk Factors | 1 | 2008 | 10482 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 506 | 0.030 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 43 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2013 | 126 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 437 | 0.020 |
Why?
| | Flow Cytometry | 1 | 1997 | 1197 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 825 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 633 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1998 | 1250 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1994 | 234 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2011 | 80 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 101 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2011 | 111 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 9 | 0.020 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 6 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 465 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7777 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 67 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 418 | 0.020 |
Why?
| | Models, Biological | 1 | 1997 | 1828 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 326 | 0.020 |
Why?
| | Cats | 1 | 2009 | 225 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 208 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 289 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 308 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 3495 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 424 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 860 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1321 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 624 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 579 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 792 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2064 | 0.010 |
Why?
| | ROC Curve | 1 | 2005 | 590 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2868 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5909 | 0.010 |
Why?
| | Spectrophotometry | 1 | 2001 | 60 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2576 | 0.010 |
Why?
| | Rheology | 1 | 2001 | 96 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 140 | 0.010 |
Why?
| | Particle Size | 1 | 2001 | 404 | 0.010 |
Why?
| | Cytosine | 1 | 1998 | 48 | 0.010 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 84 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18109 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|